Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus TRIANEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus TRIANEX.
FLOVENT DISKUS 250 vs TRIANEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
Triamcinolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
50 mg orally once daily.
None Documented
None Documented
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in severe hepatic impairment.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal elimination accounts for 20%; 10% metabolized to inactive metabolites.
Category C
Category C
Corticosteroid
Corticosteroid